5:55 PM
 | 
Oct 19, 2009
 |  BC Extra  |  Clinical News

Alnara reports liprotamase results

Alnara Pharmaceuticals Inc. (Cambridge, Mass.) said that in a Phase III trial in 145 cystic fibrosis patients who completed 12 months of treatment with liprotamase, 96% of patients maintained or gained weight at the same rate as the healthy U.S. population. The...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >